Human induced pluripotent stem cells (iPSCs) are a powerful tool for studying glial cells in vitro. Human iPS cells overcome many of the limitations of other popular models, such as immortalized cell lines and primary astrocytes, which can be plagued by reproducibility issues and lack of biological relevance. Although human iPS cells have many advantages over existing models, one drawback is that differentiation into the desired cell type is a time and labor-intensive process. To address this research bottleneck, Elixirgen Scientific provides a variety of products and services to make research more efficient. Our proprietary technology allows for rapid, reproducible differentiation of human iPSC-derived astrocytes without sacrificing purity.
Disease Modeling
iPSC-derived astrocytes from Healthy and Affected Donors
Elixirgen Scientific’s human iPSC-derived astrocyte cells are created using human iPS cells made available through a license from The California Institute for Regenerative Medicine (CIRM).
All of our iPSC-derived astrocytes are differentiated using our proprietary technology that utilizes a potent cocktail of key transcription factors to transform iPSCs into high-quality, differentiated astrocytes. The CIRM iPS cell repository includes over 1,500 iPS cell lines, so please contact us if you would like astrocytes derived from a specific donor cell line.
Advantages
- High similarity to human primary astrocytes
- No genetic footprint
- Multiple donors and disease types to choose from
Cat No.
Product Name
Disease StatusDescription
AS-SeV-CW50065
Quick-Glia™ Astrocytes - Human iPSC-derived Astrocytes (F, 74 yr donor) - Healthy Control
Healthy Control
Cryopreserved human iPSC-derived astrocytes from healthy control (F, 74)
AS-SeV-CW70067
Quick-Glia™ Astrocytes - Human iPSC-derived Astrocytes (F, 21 yr donor) - Healthy Control
Healthy Control
Cryopreserved human iPSC-derived astrocytes from healthy control (F, 21)
AS-SeV-CW50023
Quick-Glia™ Astrocytes - Human iPSC-derived Astrocytes (M, 69 yr donor) - Healthy Control
Healthy Control
Cryopreserved human iPSC-derived astrocytes from healthy control (M, 69)
AS-SeV-CW10149
Quick-Glia™ Astrocytes - Human iPSC-derived Astrocytes (M, 38 yr donor) - Healthy Control
Healthy Control
Cryopreserved human iPSC-derived astrocytes from healthy control (M, 38)
AS-SeV-CW20300
Quick-Glia™ Astrocytes - Human iPSC-derived Astrocytes (M, 10 yr donor) - Healthy Control
Healthy Control
Cryopreserved human iPSC-derived astrocytes from healthy control (M, 10)
AS-SeV-CW50025
Quick-Glia™ Astrocytes - Human iPSC-derived Astrocytes (F, 68 yr donor) - Alzheimer's Disease
Alzheimer's Disease
Cryopreserved human iPSC-derived astrocytes from Alzheimer's Disease patient (F, 68)
AS-SeV-CW50113
Quick-Glia™ Astrocytes - Human iPSC-derived Astrocytes (M, 68 yr donor) - Alzheimer's Disease
Alzheimer's Disease
Cryopreserved human iPSC-derived astrocytes from Alzheimer's Disease patient (M, 68)
AS-SeV-CW50114
Quick-Glia™ Astrocytes - Human iPSC-derived Astrocytes (F, 72 yr donor) - Alzheimer's Disease
Alzheimer's Disease
Cryopreserved human iPSC-derived astrocytes from Alzheimer's Disease patient (F, 72)
AS-SeV-CW50115
Quick-Glia™ Astrocytes - Human iPSC-derived Astrocytes (F, 67 yr donor) - Alzheimer's Disease
Alzheimer's Disease
Cryopreserved human iPSC-derived astrocytes from Alzheimer's Disease patient (F, 67)
AS-SeV-CW50137
Quick-Glia™ Astrocytes - Human iPSC-derived Astrocytes (F, 70 yr donor) - Alzheimer's Disease
Alzheimer's Disease
Cryopreserved human iPSC-derived astrocytes from Alzheimer's Disease patient (F, 70)
AS-SeV-CW50147
Quick-Glia™ Astrocytes - Human iPSC-derived Astrocytes (M, 71 yr donor) - Alzheimer's Disease
Alzheimer's Disease
Cryopreserved human iPSC-derived astrocytes from Alzheimer's Disease patient (M, 71)
AS-SeV-CW50104
Quick-Glia™ Astrocytes - Human iPSC-derived Astrocytes (M, 79 yr donor) - Alzheimer's Disease
Alzheimer's Disease
Cryopreserved human iPSC-derived astrocytes from Alzheimer's Disease patient (M, 79)
AS-SeV-CW50107
Quick-Glia™ Astrocytes - Human iPSC-derived Astrocytes (M, 72 yr donor) - Alzheimer's Disease
Alzheimer's Disease
Cryopreserved human iPSC-derived astrocytes from Alzheimer's Disease patient (M, 72)
AS-SeV-CW50169
Quick-Glia™ Astrocytes - Human iPSC-derived Astrocytes (F, 68 yr donor) - Alzheimer's Disease
Alzheimer's Disease
Cryopreserved human iPSC-derived astrocytes from Alzheimer's Disease patient (F, 68)
AS-SeV-CW50170
Quick-Glia™ Astrocytes - Human iPSC-derived Astrocytes (F, 64 yr donor) - Alzheimer's Disease
Alzheimer's Disease
Cryopreserved human iPSC-derived astrocytes from Alzheimer's Disease patient (F, 64)
AS-SeV-CW50173
Quick-Glia™ Astrocytes - Human iPSC-derived Astrocytes (F, 74 yr donor) - Alzheimer's Disease
Alzheimer's Disease
Cryopreserved human iPSC-derived astrocytes from Alzheimer's Disease patient (F, 74)
AS-SeV-CW50174
Quick-Glia™ Astrocytes - Human iPSC-derived Astrocytes (F, 76 yr donor) - Alzheimer's Disease
Alzheimer's Disease
Cryopreserved human iPSC-derived astrocytes from Alzheimer's Disease patient (F, 76)
AS-SeV-CW50175
Quick-Glia™ Astrocytes - Human iPSC-derived Astrocytes (F, 77 yr donor) - Alzheimer's Disease
Alzheimer's Disease
Cryopreserved human iPSC-derived astrocytes from Alzheimer's Disease patient (F, 77)
AS-SeV-CW50176
Quick-Glia™ Astrocytes - Human iPSC-derived Astrocytes (M, 74 yr donor) - Alzheimer's Disease
Alzheimer's Disease
Cryopreserved human iPSC-derived astrocytes from Alzheimer's Disease patient (M, 74)
AS-SeV-CW50177
Quick-Glia™ Astrocytes - Human iPSC-derived Astrocytes (F, 85 yr donor) - Alzheimer's Disease
Alzheimer's Disease
Cryopreserved human iPSC-derived astrocytes from Alzheimer's Disease patient (F, 85)
AS-SeV-CW60130
Quick-Glia™ Astrocytes - Human iPSC-derived Astrocytes (F, 6 yr donor) - Epilepsy
Epilepsy
Cryopreserved human iPSC-derived astrocytes from Epilepsy patient (F, 6)
AS-SeV-CW60231
Quick-Glia™ Astrocytes - Human iPSC-derived Astrocytes (M, 6 yr donor) - Epilepsy
Epilepsy
Cryopreserved human iPSC-derived astrocytes from Epilepsy patient (M, 6)
AS-SeV-CW60236
Quick-Glia™ Astrocytes - Human iPSC-derived Astrocytes (F, 11 yr donor) - Epilepsy
Epilepsy
Cryopreserved human iPSC-derived astrocytes from Epilepsy patient (F, 11)
AS-SeV-CW20026
Quick-Glia™ Astrocytes - Human iPSC-derived Astrocytes (M, 10 yr donor) - Autism Spectrum Disorder
Autism Spectrum Disorder
Cryopreserved human iPSC-derived astrocytes from Autism Spectrum Disorder patient (M, 10)
AS-SeV-CW20090
Quick-Glia™ Astrocytes - Human iPSC-derived Astrocytes (F, 18 yr donor) - Autism Spectrum Disorder
Autism Spectrum Disorder
Cryopreserved human iPSC-derived astrocytes from Autism Spectrum Disorder patient (F, 18)
AS-SeV-CW10130
Quick-Glia™ Astrocytes - Human iPSC-derived Astrocytes (M, 36 yr donor) - Fatty Liver Disease
Fatty Liver Disease
Cryopreserved human iPSC-derived astrocytes from Fatty Liver Disease patient (M, 36)
You might also be interested in....
Quick-Glia™ Astrocyte Differentiation Kits & Media
Our Quick-Glia™ Astrocyte differentiation kits allow researchers to quickly, easily, and efficiently differentiate their iPS cell line into astrocytes. The kit uses Sendai virus to over-express transcription factors to iPS cells and does not leave a genetic footprint.
Characterization
Figure 1. Immunofluorescent staining of Quick-Glia™ Astrocyte shows expression of astrocytic markers CD44, ALDH1L1, and GFAP. Nuclei are counterstained with Hoechst 33342 (cyan) (scale bar = 100 μm). All images are pseudo-colored.
Figure 1

Figure 2

Figure 2. (A) Gene expression profiles of iPSCs and Quick-Glia™ – Astrocyte SeV Culture on day 28 were compared with the profile of human primary astrocytes and the results are shown as scatter plots. The horizontal axis indicates the expression levels of genes in human primary astrocytes purchased from ScienCell (Catalog Number: 1800-5), whereas the vertical axis indicates the expression levels of genes in iPSCs (left) and in Quick-Glia™ – Astrocyte SeV Culture on day 28 (right). The levels of gene expression are shown based on transcripts per million (TPM) in the log10 scale. Blue and green dots represent upregulated and downregulated genes (FDR<0.05), respectively, relative to their levels in human primary astrocytes. (B) Similarities of gene expression profiles of human iPSCs and Quick-Glia™ – Astrocyte SeV Culture on days 14, 28 and 42 to the profile of human primary astrocytes are shown as a bar chart. The vertical axis indicates Pearson correlation (r) based on median-subtracted logTPM.
Figure 3. Real-time quantitative PCR analysis of expression levels of astrocyte-associated genes CD44, GFAP, S100β and ALDH1L1 were examined. Graphs show comparison of Quick-Glia™ – Astrocyte SeV Culture on day 28 (A) and day 42 (B) with human brain total RNA (TaKaRa, Catalog Number: 636530). The relative gene expression is normalized to phosphoglycerate kinase 1 (PGK1), and then calculated as a fold induction relative to undifferentiated hPSCs as a control. Error bars show standard deviation.
Figure 3

Figure 4

Figure 4. Human iPSCs (negative control), human primary astrocytes (hpA, positive control) and Quick-Glia™ Astrocytes at days 42 and 56 post-differentiation were exposed to 100µM L-glutamate for 60 minutes. The amount of glutamate cleared was determined using a Promega Glutamate-Glo assay kit. Bar graph represents 3 biological replicates. Error bars show SD.
Human primary astrocytes (ScienCell Research Laboratories, Catalog number: 1800) and Quick-Glia - Astrocyte SeV kit cultures, harvested at either 28 days or 42 days post SeV infection, were plated at 7,800 cells/cm2 in a Geltrex-coated 96-well plate (Corning, Catalog number: 353072) and grown in ScienCell Astrocyte medium (ScienCell Research Laboratories, without FBS, Catalog number: 1801) for 14 days. As a negative control, human iPSCs were plated in StemFit Basic04 medium (Ajinomoto, Catalog number: ASB04-C) two days before assay measurement using the plating density stated above. 30 minutes prior to assay execution, culture medium was replaced with Hanks' Balanced Salt Solution (HBSS) without phenol red (Fisher Scientific, Catalog number: 14025092). Subsequently, cells were exposed to 100µM L-glutamate (Tocris, Catalog number: 0218) in HBSS for 60 minutes. Immediately after the assay, solution was collected and cells were dislodged using a 1:1 mixture of TrypLE Select Enzyme (Fisher Scientific, Catalog number: 12563029) and 0.02% EDTA (Lonza, Catalog number: 17-711E). The numbers of live cells were determined using a NucleoCounter NC-200 (Chemometec, Catalog number: 900-0200) cell counter. Glutamate concentration was measured by a bioluminescence-based Glutamate-Glo assay kit (Promega, Catalog number: J7021) and a SPECTRAFluor Plus microplate reader (Tecan). To determine the amount of glutamate cleared, all values were first background signal-subtracted using a HBSS only sample and concentrations were thereafter acquired from the glutamate titration curve according to manufacturer’s instructions.
Frequently Asked Questions
Do I need a license for commercial use of Elixirgen’s iPSC astrocyte cells?
No. The use of differentiated cells provided by Elixirgen Scientific does not require any additional license from other parties for any type of use, except for use in humans or for therapeutic or diagnostic use.
What sizes of the Quick-Glia™ Astrocyte – SeV Kit are available?
Off the shelf, we offer a set of reagents for use with a total of 4 wells of a 24-well plate and 6 wells of a 6-well plate. If you are looking for a larger quantity, please contact us for pricing information.